期刊
ANNALS OF NEUROLOGY
卷 69, 期 2, 页码 248-256出版社
WILEY
DOI: 10.1002/ana.22319
关键词
-
资金
- Japan Ministry of Education, Science, Sports, and Culture [18590948]
- Japanese Ministry of Health, Labor, and Welfare [H15-Kokoro-001]
- Japan Science and Technology Agency
- Kakihara Science and Technology Research Foundation
- Japan Brain Foundation
- Grants-in-Aid for Scientific Research [23890150, 22590936, 18590948] Funding Source: KAKEN
Objective: Intracellular amyloid beta-protein (A beta) contributes to neurodegeneration in Alzheimer disease (AD). Apomorphine (APO) is a dopamine receptor agonist for Parkinson disease and also protects against oxidative stress. Efficacy of APO for an AD mouse model and effects of APO on cell cultures are studied. Methods: The triple transgenic AD mouse model (3xTg-AD) has 2 familial AD-related gene mutations (APP(KM670/671NL)/PS1(M146V)) and a tau gene mutation (Tau(P301L)). Six-month-old 3xTg-AD mice were treated with subcutaneous injections of APO once a week for 1 month. Memory function was evaluated by Morris water maze before and after the treatment. Brain tissues were examined by immunohistochemical staining and Western blotting. Effects of APO on intracellular A beta degradation, activity of A beta-degrading enzymes, and protection against oxidative stress were studied in cultured SH-SY5Y cells. Results: After APO treatment, short-term memory function was dramatically improved. Significant decreases in the levels of intraneuronal A beta, hyper-phosphorylated tau (p-tau), p53, and heme oxygenase-1 proteins were observed. Moreover, APO promoted degradation of intracellular A beta, increased activity of proteasome and insulin-degrading enzyme, protected against H2O2 toxicity, and decreased p53 protein levels in the cultured cells. Interpretation: 3xTg-AD mice show intraneuronal A beta accumulation and memory disturbances before extracellular A beta deposition. Our data demonstrating improvement of memory function of 3xTg-AD mice with decreases in intraneuronal A beta and p-tau levels by APO treatment strongly suggest that intraneuronal A beta is an important therapeutic target and APO will be a novel drug for AD. ANN NEUROL 2011;69:248-256
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据